ARTICLE | Finance
Cross court
How Ra courted crossover investors for its series B
August 17, 2015 7:00 AM UTC
For private companies looking to court crossover investors, the lesson from Ra Pharmaceuticals Inc.'s $58.5 million series B round is that having a well-connected board is paramount.
"We had a board meeting last September when the discussion was about socializing the message," said President and CEO Doug Treco. "I wouldn't call it testing the waters; we were just out there getting more people aware of the story for the future." ...